BioSpace News Archive

SQZ Biotechnologies announced that the company’s first generation, integrated point-of-care cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specifications relative to current clean room-based processes used in clinical development.

Arecor Therapeutics plc, the biopharmaceutical group advancing ’s therapies to enable healthier lives, today announces that it will host a key opinion leader webinar entitled “The Need for Concentrated and Rapid Acting Insulin Treatments in Diabetes Care”, on Thursday 26 May, 2022, at 15:00-16:30 BST.

The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab 1.

Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present virtually at the 2022 H.C. Wainwright Global Investment Conference being held May 23-26, 2022.

Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting.

Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a license agreement and extended a research collaboration with the University of Alberta, a leading Canadian research university, focused on identifying and testing broad-spectrum antiviral drugs against future variants of SARS-CoV-2 and other emerging viruses.

Ikena Oncology, Inc. announced that management will be presenting at the H.C. Wainwright Global Investment Conference, taking place May 23-26, 2022, and the Jefferies Global Healthcare Conference, taking place June 8-10, 2022.

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win ® technology platform, announced today that it has dosed the first patient in its Phase 3 IOB-013 / KN-D18 trial (NCT05155254).

CareDx, Inc. announced that the International Society for Heart and Lung Transplantation has selected Dr. Berta Sáez-Giménez as the winner of the CareDx sponsored ISHLT Innovation Challenge Award.